文献速递系统性红斑狼疮

美国风湿病学会系统性红斑狼疮质量指标的制定:采用改良德尔菲法并结合风湿病学有效性信息学系统(RISE)登记数据回顾

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-06-19

美国风湿病学会工作组采用改良德尔菲法,回顾2000至2020年北美和欧洲指南,提炼57个质量构念并形成15项质量指标声明;多学科专家组投票后,5项在重要性和可行性上达成高度共识,最终推荐3项指标:羟氯喹使用、限制泼尼松等效剂量>7.5 mg/天不超过6个月、每至少6个月监测肾功能和尿蛋白排泄。

要点

  • 工作组从指南中提炼57个质量构念,形成15项质量指标声明。
  • 5项声明在重要性和可行性上达成高度共识,其中2项关于治疗、3项关于实验室监测。
  • 最终推荐3项指标:羟氯喹使用、限制糖皮质激素>7.5 mg/天不超过6个月、每至少6个月监测肾功能和尿蛋白排泄。

核心结论

  • 德尔菲流程为系统性红斑狼疮(SLE)诊疗选出了3项质量指标:羟氯喹使用、糖皮质激素减量、肾脏监测。
  • 下一步这些指标将在RISE登记和美国风湿病学实践中进行规格化与效度检验,作为全国实施和质量改进项目的基础。

研究设计与样本

  • 美国风湿病学会(ACR)SLE专家工作组采用改良德尔菲法,回顾2000至2020年北美和欧洲关于SLE治疗、监测和表型的全部指南。
  • 工作组成员从指南中提取质量构念,按重要性和可行性评分,并生成循证质量指标声明。
  • 查询ACR风湿病学有效性信息学系统(RISE)登记以评估测量数据可得性。
  • 在连续3轮德尔菲会议中,多学科德尔菲专家组对每项声明的重要性和可行性进行投票。
  • 对在可行性和重要性上达成共识的拟议指标进行排序,以确定前3项指标。

主要发现

  • 指南回顾和质量构念提炼共产生57个质量构念,形成15项质量指标声明。
  • 15项声明中,5项在重要性和可行性上达到高度共识,包括2项治疗指标和3项实验室监测指标。
  • 排名最高的3项声明被推荐进一步规格化为SLE数字质量指标:羟氯喹使用、限制糖皮质激素>7.5 mg/天至<6个月、每至少6个月监测肾功能和尿蛋白排泄。

关键数值与推荐

  • 推荐进一步规格化的3项SLE数字质量指标为:①羟氯喹使用;②限制糖皮质激素使用>7.5 mg/天至<6个月;③每至少6个月监测肾功能和尿蛋白排泄。
  • 15项质量指标声明中,5项在重要性和可行性上达到高度共识(2项治疗、3项实验室监测)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to develop readily measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a multistep process guided by consensus methods. METHODS: Using a modified Delphi process, an American College of Rheumatology (ACR) workgroup of SLE experts reviewed all North American and European guidelines from 2000 to 2020 on treatment, monitoring, and phenotyping of patients with lupus. Workgroup members extracted quality constructs from guidelines, rated these by importance and feasibility, and generated evidence-based quality measure statements. The ACR Rheumatology Informatics System for Effectiveness (RISE) Registry was queried for measurement data availability. In 3 consecutive Delphi sessions, a multidisciplinary Delphi panel voted on the importance and feasibility of each statement. Proposed measures with consensus on feasibility and importance were ranked to identify the top 3 measures. RESULTS: Review of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. Among these, 5 met high consensus for importance and feasibility, including 2 on treatment and 3 on laboratory monitoring measures. The 3 highest-ranked statements were recommended for further measure specification as SLE digital quality measures: 1) hydroxychloroquine use, 2) limiting glucocorticoid use >7.5 mg/day to <6 months, and 3) end-organ monitoring of kidney function and urine protein excretion at least every 6 months. CONCLUSION: The Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring. Next, measures will undergo specification and validity testing in RISE and US rheumatology practices as the foundation for national implementation and use in quality improvement programs.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Bartels CM, Jorge A, Feldman CH, et al. Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review. Arthritis Care Res (Hoboken). 2023. PMID: 37165898. doi:10.1002/acr.25143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。